Loading...
Loading...
AXNX| Name | Value |
|---|---|
| Revenues | 91.4M |
| Cost of Revenue | 22.2M |
| Gross Profit | 69.3M |
| Operating Expense | 84.6M |
| Operating I/L | -19.2M |
| Other Income/Expense | 3.9M |
| Interest Income | 4.0M |
| Pretax | -15.3M |
| Income Tax Expense | 3.8M |
| Net Income/Loss | -19.1M |
Axonics, Inc. is a medical technology company specializing in sacral neuromodulation (SNM) systems for treating overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the sacral nerve, reducing symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent for female stress urinary incontinence. Axonics sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally.
